Guggenheim Capital LLC Amylyx Pharmaceuticals, Inc. Transaction History
Guggenheim Capital LLC
- $13.3 Billion
- Q3 2025
A detailed history of Guggenheim Capital LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 24,899 shares of AMLX stock, worth $315,968. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,899
Previous 35,752
30.36%
Holding current value
$315,968
Previous $229,000
47.6%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AMLX
# of Institutions
183Shares Held
94.1MCall Options Held
421KPut Options Held
174K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...